Citi Keeps Their Sell Rating on Novavax (NVAX)
In a report released today, from Citi maintained a Sell rating on Novavax, with a price target of $6.00.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
In addition to Citi, Novavax also received a Sell from Bank of America Securities’s Alec Stranahan in a report issued on January 22. However, today, TipRanks – Anthropic reiterated a Hold rating on Novavax (NASDAQ: NVAX).
Based on Novavax’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $70.45 million and a GAAP net loss of $202.38 million. In comparison, last year the company earned a revenue of $84.51 million and had a GAAP net loss of $121.3 million
Read More on NVAX:
Disclaimer & DisclosureReport an Issue
- Novavax Soars as Traders Bet Big on Vaccine Future
- Novavax call volume above normal and directionally bullish
- Novavax: Execution Risks, Long-Dated Cash Flows, and COVID Market Headwinds Undermine Profitability Outlook
- Novavax: Pfizer Partnership Validates Matrix‑M Platform and Supports Upside in Capital‑Light Growth Strategy
- Novavax price target raised to $7 from $6 at BofA
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.